Table 1 Clinical characteristics of ventilated and non ventilated patients

Gender (M/F)

8/7

1/7

Age

47.00 (15.55)

37.50 (15.12)

Pandemic influenza vaccine (yes/no)

0/15

0/8

Chronic respiratory disease (yes/no)

3/12

2/6

Renal disease (yes/no)

1/14

2/6

Cardiovascular disease (yes/no)

2/13

0/8

Neurological disease (yes/no)

3/12

1/7

Cancer (yes/no)

0/15

1/7

Obesity (BMI > 30) (yes/no)

1/14

1/7

Diabetes (yes/no)

2/13

0/8

Pregnancy (yes/no)

1/14

2/6

Dyslipemia (yes/no)

2/13

0/8

Alcoholism (yes/no)

0/15

2/6

Smoker (yes/no)

9/6

4/4

Fatal outcome/survivors

7/8

0/8

Duration of symptoms at ICU admission

4.9 (3.6)

5.0 (2.2)

Pa O2/Fi O2

120.9 (55.5)

153.8 (69.7)

Days at hospital

20.9 (26.2)

4.5 (1.9)

Days since onset to intubation

5.1 (3.7)

n.a

Oseltamivir

15/0

8/0

Duration of symptoms before oseltamivir

4.8 (3.7)

4.6 (2.4)

Bilateral infiltrates in chest X-Ray at admission to ICU (yes/no)

14/1

6/2

Bacterial overinfection during hospitalization (yes/no)

(resp culture-RC; hemoculture-HC)

4/11

S. marcescens RC, HC

S. aureus RC

P. aeruginosa RC

A. baumanii RC

0/8

Presence of specific antibodies against 2009 pandemic influenza at admission to ICU (titre > 1/40) (yes/no)

2/13

2/6

SOFA

6.4 (2.8)

4.0 (1.0)

Creatinine (ref value: 0.5 - 1.2 mg/dl)

0.8 (0.4)

1.9 (3.0)

AST (ref value: 2-38 U/l)

91.2 (65.3)

73.8 (39.9)

ALT (ref value: 2-41 U/l)

43.1 (31.0)

75.6 (59.9)

CPK (ref value: 24- 194 U/ml)

850.7 (827.0)

449.0 (697.8)

Leucocytes (4500-10000/mm ³)

6277.8 (3189.6)

7258.7 (3973.6)

Neutrophils (1900-8000/mm ³)

5431.0 (2888.6)

6268.6 (3771.4)

Lymphocytes (900-5200/mm ³)

691.5 (445.6)

636.5 (340.8)